ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)
09 nov. 2022 08h00 HE
|
Oryzon Genomics, S.A.
Collaborative study with Fox Chase Cancer Center (FCCC)Oryzon and FCCC will collaborate to assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs MADRID and SPAIN and...
ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference
07 nov. 2022 08h00 HE
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON to Give Updates on Corporate Progress in November
04 nov. 2022 08h00 HE
|
Oryzon Genomics, S.A.
Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022 MADRID, Spain and BOSTON, Nov. 04,...
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022
02 nov. 2022 07h00 HE
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON to Give Updates on Corporate Progress in October
03 oct. 2022 08h00 HE
|
Oryzon Genomics, S.A.
Chardan's 6th Annual Genetic Medicines Conference MSD European Business Development Outreach Iberian Digital Forum AACR Special Conference: Cancer Epigenomics Brain Innovation Days HealthTech...
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
16 sept. 2022 08h00 HE
|
Oryzon Genomics, S.A.
At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23 MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
ORYZON to Give Updates on Corporate Progress in September
08 sept. 2022 08h00 HE
|
Oryzon Genomics, S.A.
H.C. Wainwright Global Investment Conference10th European Conference on Mental HealthSachs Annual Biotech in Europe ForumAnnual RAS-Targeted Drug Development SummitXIX Congress of the Spanish Society...
ORYZON Collaborates with the CMT Research Foundation in the US
26 juil. 2022 08h00 HE
|
Oryzon Genomics, S.A.
To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth diseaseCMTRF to provide funding for in vivo efficacy tests in CMT preclinical model MADRID and BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- ...
ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022
22 juil. 2022 08h00 HE
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers
19 juil. 2022 08h00 HE
|
Oryzon Genomics, S.A.
Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and solid tumors MADRID, Spain and BOSTON, July 19, 2022 (GLOBE...